Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion, inactivated)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Fluarix Tetra is a quadrivalent, inactivated, split-virion influenza vaccine developed and manufactured by GSK. It is designed to provide active immunization against four strains of influenza virus: two influenza A subtypes (typically H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine is produced using an egg-based manufacturing process where the virus is inactivated and then chemically split. It is updated annually to match the specific strains recommended by the World Health Organization (WHO) and national regulatory authorities for each influenza season. Fluarix Tetra is administered via intramuscular injection and is indicated for the prevention of seasonal influenza in individuals aged 6 months and older.
- Brand names
- Fluarix TetraAlphaRix TetraInflusplit TetraFluarix Quadrivalent
- Other names
- Quadrivalent Split Virion Influenza VaccineFLU D-QIVFLU-Q-QIVQuadrivalent Seasonal Influenza Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (split virion, inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion, inactivated).